title: Novel chenodeoxycholic acid-sodium alginate matrix in the microencapsulation of the potential antidiabetic drug, probucol. An in vitro study.
abstract: BACKGROUND
  We previously designed, developed and characterized a novel microencapsulated formulation as a platform for the targeted delivery of Probucol (PB) in an animal model of Type 2 Diabetes.
  
  
  OBJECTIVE
  The objective of this study is to optimize this platform by incorporating Chenodeoxycholic acid (CDCA), a bile acid with good permeation-enhancing properties, and examine its effect in vitro. Using sodium alginate (SA), we prepared PB-SA (control) and PB-CDCA-SA (test) microcapsules.
  
  
  CONCLUSIONS
  CDCA resulted in better structural and surface characteristics, uniform morphology, and stable chemical and thermal profiles, while size and rheological parameters remained unchanged. PB-CDCA-SA microcapsules showed good excipients' compatibilities, as evidenced by differential scanning calorimetry (DSC), Fourier transform infrared spectroscopy, scanning electron microscopy and energy dispersive X-ray spectroscopy studies. CDCA reduced microcapsule swelling at pH 7.8 at both 37 °C and 25 °C and improved PB-release.
  
  
  CONCLUSIONS
  CDCA improved the characteristics and release properties of PB-microcapsules and may have potential in the targeted oral delivery of PB.
authors.affiliation: a Biotechnology and Drug Development Research Laboratory, School of Pharmacy, Curtin Health Innovation Research Institute, Curtin University , Perth, Western Australia , Australia .
authors.forename: Armin
authors.initials: A
authors.lastname: Mooranian
authors.forename: Rebecca
authors.initials: R
authors.lastname: Negrulj
authors.forename: Momir
authors.initials: M
authors.lastname: Mikov
authors.forename: Svetlana
authors.initials: S
authors.lastname: Golocorbin-Kon
authors.forename: Frank
authors.initials: F
authors.lastname: Arfuso
authors.forename: Hani
authors.initials: H
authors.lastname: Al-Salami
mesh_terms: D000284:Administration, Oral; D000464:Alginates / Q000737:chemistry*; D001647:Bile Acids and Salts / Q000737:chemistry; D002152:Calorimetry, Differential Scanning; D002214:Capsules; D002635:Chenodeoxycholic Acid / Q000737:chemistry*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D004339:Drug Compounding; D016503:Drug Delivery Systems; D004355:Drug Stability; D020723:Glucuronic Acid / Q000737:chemistry; D006603:Hexuronic Acids / Q000737:chemistry; D006801:Humans; D006863:Hydrogen-Ion Concentration; D008855:Microscopy, Electron, Scanning; D010316:Particle Size; D011208:Powders; D011341:Probucol / Q000737:chemistry*; D012212:Rheology; D017550:Spectroscopy, Fourier Transform Infrared; D013499:Surface Properties; D013696:Temperature; D014783:Viscosity; D055114:X-Ray Microtomography
chemical_list: D000464:Alginates; D001647:Bile Acids and Salts; D002214:Capsules; D006603:Hexuronic Acids; D011208:Powders; D002635:Chenodeoxycholic Acid; D020723:Glucuronic Acid; D011341:Probucol
keywords: Bile acids; Type 2 diabetes mellitus; chenodeoxycholic acid; microencapsulation; probucol